ENDURONYL FORTE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ENDURONYL FORTE (ENDURONYL FORTE).
Enduronyl Forte is a combination of methyclothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule, and deserpidine, a Rauwolfia alkaloid that depletes catecholamines from adrenergic nerve endings, resulting in reduced peripheral vascular resistance and CNS sedation.
| Metabolism | Methyclothiazide is not extensively metabolized and is excreted unchanged by the kidneys. Deserpidine is metabolized in the liver via hydrolysis and conjugation. |
| Excretion | Renal: ~50% unchanged; Biliary/Fecal: ~50% as metabolites and unchanged drug. |
| Half-life | Terminal elimination half-life: 24-48 hours (avg. 36 h); due to long half-life, requires caution in renal impairment. |
| Protein binding | ~90% bound to plasma proteins (primarily albumin). |
| Volume of Distribution | Vd: 2-4 L/kg; indicates extensive tissue distribution. |
| Bioavailability | Oral: ~70% (well absorbed, but first-pass metabolism reduces bioavailability). |
| Onset of Action | Oral: 2-4 hours (antihypertensive effect). |
| Duration of Action | Oral: 12-24 hours; clinical effect may persist up to 48 h due to slow elimination. |
Oral: Initial 2.5-5 mg once daily; increase as needed to maximum 20 mg once daily.
| Dosage form | TABLET |
| Renal impairment | GFR 30-59 mL/min: 1.25-2.5 mg once daily; GFR 15-29 mL/min: 0.625-1.25 mg once daily; GFR <15 mL/min: not recommended. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated. |
| Pediatric use | Not recommended for patients <18 years due to lack of safety data. |
| Geriatric use | Start at 1.25 mg once daily; increase slowly to avoid hypotension and electrolyte imbalance. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ENDURONYL FORTE (ENDURONYL FORTE).
| Breastfeeding | Thiazides and reserpine are excreted into breast milk. Likely M/P ratio not established; thiazides are found in low concentrations but reserpine may accumulate. Use is not recommended due to potential for infant electrolyte imbalances, hypotension, and extrapyramidal effects. Alternatives should be considered. |
| Teratogenic Risk | ENDURONYL FORTE (methylothiazide 5mg, deserpidine 0.5mg) is contraindicated in pregnancy. First trimester: Thiazide diuretics cross placenta and are associated with increased risk of congenital anomalies, particularly neural tube defects and cardiovascular malformations. Second and third trimesters: Risk of fetal/neonatal adverse effects including electrolyte disturbances, thrombocytopenia, jaundice, and hypotension. Deserpidine (Rauwolfia alkaloid) may cause neonatal bradycardia, respiratory depression, and hypotonia if used near term. |
■ FDA Black Box Warning
None
| Serious Effects |
["History of hypersensitivity to thiazides or sulfonamides","Anuria (with methyclothiazide)","History of severe mental depression or suicidal tendencies (with deserpidine)","Active peptic ulcer disease (with deserpidine)","Electroconvulsive therapy (use within 7 days)","Pheochromocytoma"]
| Precautions | ["May cause electrolyte disturbances including hypokalemia, hyponatremia, and hypomagnesemia","May precipitate azotemia in patients with renal impairment","May cause severe mental depression and suicidal ideation with deserpidine","May increase lithium toxicity","May cause photosensitivity and systemic lupus erythematosus exacerbation","Use caution in patients with hepatic disease due to risk of hepatic coma","May cause hyperglycemia and hyperuricemia"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, serum electrolytes (especially sodium, potassium), uric acid, and renal function. Fetal monitoring includes ultrasound for growth and amniotic fluid volume (risk of oligohydramnios). Neonatal monitoring for hypoglycemia, electrolyte disturbances, and thrombocytopenia. |
| Fertility Effects | Limited data. Thiazides may cause sexual dysfunction in males but no direct evidence of impaired fertility. Reserpine can cause decreased libido and gynecomastia. Effects on female fertility are unknown. |